Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients

NCT04940546 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: Sintilimab
DRUG: Oxaliplatin
DRUG: Capecitabine
DRUG: Bevacizumab

Sponsor

Sun Yat-sen University